Market cap of Palisade Bio Inc. [PALI] reaches 8.33M – now what?

Palisade Bio Inc. [NASDAQ: PALI] gained 17.20% on the last trading session, reaching $0.11 price per share at the time. The company report on September 29, 2022 that Palisade Bio Announces Oral Presentation of Phase 2 Data at the American College of Surgeons (ACS) Clinical Congress 2022.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced its abstract was accepted for presentation at the American College of Surgeons (ACS) Clinical Congress 2022 being held October 16-20, 2022, in San Diego, CA.

Palisade Bio Inc. represents 71.24 million in outstanding shares, while the company has a total market value of $8.33 million with the latest information. PALI stock price has been found in the range of $0.099 to $0.1288.

If compared to the average trading volume of 4.61M shares, PALI reached a trading volume of 12347597 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here is what top equities market gurus are saying about Palisade Bio Inc. [PALI]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for PALI shares is $1.50 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on PALI stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

The Average True Range (ATR) for Palisade Bio Inc. is set at 0.01 The Price to Book ratio for the last quarter was 0.55, with the Price to Cash per share for the same quarter was set at 0.07.

Trading performance analysis for PALI stock

Palisade Bio Inc. [PALI] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 5.34. With this latest performance, PALI shares dropped by -22.48% in over the last four-week period, additionally sinking by -88.99% over the last 6 months – not to mention a drop of -95.29% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for PALI stock in for the last two-week period is set at 35.53, with the RSI for the last a single of trading hit 41.01, and the three-weeks RSI is set at 34.05 for Palisade Bio Inc. [PALI]. The present Moving Average for the last 50 days of trading for this stock 0.2187, while it was recorded at 0.1042 for the last single week of trading, and 0.7039 for the last 200 days.

Palisade Bio Inc. [PALI]: A deeper dive into fundamental analysis

Palisade Bio Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.60 and a Current Ratio set at 2.60.

An analysis of insider ownership at Palisade Bio Inc. [PALI]

There are presently around $0 million, or 1.50% of PALI stock, in the hands of institutional investors. The top three institutional holders of PALI stocks are: VANGUARD GROUP INC with ownership of 271,604, which is approximately 0% of the company’s market cap and around 0.30% of the total institutional ownership; SARGENT INVESTMENT GROUP, LLC, holding 240,000 shares of the stock with an approximate value of $28000.0 in PALI stocks shares; and GEODE CAPITAL MANAGEMENT, LLC, currently with $15000.0 in PALI stock with ownership of nearly 2.427% of the company’s market capitalization.

Positions in Palisade Bio Inc. stocks held by institutional investors increased at the end of November and at the time of the November reporting period, where 11 institutional holders increased their position in Palisade Bio Inc. [NASDAQ:PALI] by around 248,298 shares. Additionally, 7 investors decreased positions by around 156,228 shares, while 12 investors held positions by with 566,995 shares. The mentioned changes placed institutional holdings at 971,521 shares, according to the latest SEC report filing. PALI stock had 5 new institutional investments in for a total of 83,868 shares, while 4 institutional investors sold positions of 128,608 shares during the same period.


Please enter your comment!
Please enter your name here